Adaptimmune Therapeutics plc (ADAP) stock rallied over 0.58% intraday to trade at $1.74 a share on NASDAQ. The stock opened with a gain of 1.16% at $1.75 and touched an intraday high of $1.85, rising 0.58% against the last close of $1.73. The stock went to a low of $1.66 during the session.
Number of Shares
Cash Flow per Share
Free Float in %
Sales or Revenue6.15 Million
5Y Sales Change-15.40%
Fiscal Year Ends2021-12-30
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc. Adaptimmune Therapeutics plc also has a strategic collaboration and license agreement with Genentech, Inc. to develop and commercialize allogeneic cell therapies to treat various oncology indications. The company was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Adaptimmune Therapeutics plc (NASDAQ: ADAP) stock price is $1.74 as of the last check on Thursday, June 23. During the trading session, ADAP stock reached the peak price of $1.85 while $1.66 was the lowest point it dropped to.
The NASDAQ listed ADAP is part of Biotechnology industry that operates in the broader Health Care sector. Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets.
Dr. Arundathy Nirmalini Pandite M.B.A., M.D.
Sr. VP of Clinical Devel.
Mr. Adrian G. Rawcliffe
CEO, Principal Accounting Officer & Director
Dr. Helen Katrina Tayton-Martin MBA, Ph.D.
Co-Founder & Chief Bus. Officer
Mr. Gavin Hilary James Wood BA (Hons), ACA
Chief Financial Officer
ADAP stock traded closed the last session at $1.74, which is $0.01 or 0.58% lower than its previous close of $1.73. ADAP's current trading price is 38.10% lower than its 52-week high of $6.86 where as its distance from 52-week low of 1.26% is -74.64%.
Number of ADAP employees currently stands at -. ADAP operates from 60 Jubilee Avenue, Milton Park, Abingdon OX14 4RX, United Kingdom.
Official Webiste of $ADAP is: https://www.adaptimmune.com
ADAP stock volume for the day was 683,563 shares while in the previous session number of ADAP shares traded was 683,800 . The average number of ADAP shares traded daily for last 3 months was 563.95 Thousands.
The percentage change in ADAP stock occurred in the recent session was 0.58% while the dollar amount for the price change in ADAP stock was $0.01.
In the recent session, the day high for ADAP stock was $1.85 while the low for ADAP stock touched on the day was $1.66.
The market value of ADAP currently stands at 253.38 Million with its latest stock price at $1.74 and 156.67 Million of its shares outstanding.